Cape Investment Advisory Inc. Boosts Position in IQVIA Holdings Inc. (NYSE:IQV)

Cape Investment Advisory Inc. grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQVFree Report) by 1.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 8,269 shares of the medical research company’s stock after acquiring an additional 92 shares during the quarter. IQVIA comprises 0.9% of Cape Investment Advisory Inc.’s investment portfolio, making the stock its 16th largest position. Cape Investment Advisory Inc.’s holdings in IQVIA were worth $1,913,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. Primecap Management Co. CA boosted its position in shares of IQVIA by 0.3% during the 4th quarter. Primecap Management Co. CA now owns 313,336 shares of the medical research company’s stock valued at $72,500,000 after acquiring an additional 960 shares during the last quarter. Johnson Financial Group Inc. lifted its position in IQVIA by 806.6% in the 4th quarter. Johnson Financial Group Inc. now owns 1,233 shares of the medical research company’s stock worth $285,000 after buying an additional 1,097 shares during the last quarter. Nomura Asset Management Co. Ltd. lifted its position in IQVIA by 2.0% in the 4th quarter. Nomura Asset Management Co. Ltd. now owns 48,057 shares of the medical research company’s stock worth $11,119,000 after buying an additional 954 shares during the last quarter. Nixon Peabody Trust Co. lifted its position in IQVIA by 603.7% in the 4th quarter. Nixon Peabody Trust Co. now owns 68,585 shares of the medical research company’s stock worth $15,869,000 after buying an additional 58,839 shares during the last quarter. Finally, Team Hewins LLC bought a new stake in IQVIA in the 4th quarter worth approximately $214,000. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, insider Kevin C. Knightly sold 8,607 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the sale, the insider now owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Trading Up 1.1 %

Shares of IQV traded up $2.51 during mid-day trading on Friday, hitting $229.60. 751,380 shares of the company’s stock traded hands, compared to its average volume of 893,862. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a market capitalization of $41.83 billion, a P/E ratio of 31.37, a PEG ratio of 2.09 and a beta of 1.52. The business’s 50-day moving average price is $237.13 and its 200-day moving average price is $228.73.

IQVIA (NYSE:IQVGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion for the quarter, compared to analysts’ expectations of $3.69 billion. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on IQV shares. Evercore ISI dropped their target price on IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. BTIG Research started coverage on IQVIA in a research report on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Truist Financial dropped their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Barclays boosted their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $257.57.

Check Out Our Latest Stock Analysis on IQV

IQVIA Profile

(Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQVFree Report).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.